Progress in the development of matrix metalloproteinase inhibitors

被引:88
|
作者
Tu, GuoGang [1 ,2 ]
Xu, WenFang
Huang, HuiMing [2 ]
Li, ShaoHua [2 ]
机构
[1] Shandong Univ, Dept Med Chem, Sch Pharmaceut Sci, Jinan 250012, Peoples R China
[2] NanChang Univ, Coll Med, Dept Pharm, Nanchang 330006, Peoples R China
关键词
matrix metalloproteinases; MMP inhibitors; Zinc-binding groups; cancer; computer-aided drug design; angiogenesis; metastasis; proteases;
D O I
10.2174/092986708784567680
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Matrix metalloproteinases ( MMPs) are a family of zinc-dependent proteinases involved in the degradation and remodeling of extracellular matrix proteins that are associated with the tumorigenic process. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful for the treatment of diseases such as cancer, osteoarthritis, and rheumatoid arthritis. A vast number of MMPIs have been developed in recent years. With the failure of these inhibitors in clinical trials, more efforts have been directed to the design of specific inhibitors with different Zn-binding groups. This review summarizes the current status of MMPIs, the design of small molecular weight MMPIs, a brief description of available three-dimensional MMP structures, a review of the proposed therapeutic utility of MMPIs, and a clinical update of compounds that have entered clinical trials in humans.
引用
收藏
页码:1388 / 1395
页数:8
相关论文
共 50 条
  • [1] Progress in the design of matrix metalloproteinase inhibitors
    Cheng, F
    Liu, H
    Luo, XM
    Jiang, HL
    Shen, JK
    Chen, KX
    Ji, RY
    PROGRESS IN CHEMISTRY, 2001, 13 (04) : 283 - 293
  • [2] Development of matrix metalloproteinase inhibitors in cancer therapy
    Hidalgo, M
    Eckhardt, SG
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (03): : 178 - 193
  • [3] Development of matrix metalloproteinase inhibitors in cancer therapy
    Purcell, WT
    Rudek, MA
    Hidalgo, M
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2002, 16 (05) : 1189 - +
  • [4] Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection
    Bencsik, Peter
    Kupai, Krisztina
    Goerbe, Aniko
    Kenyeres, Eva
    Varga, Zoltan V.
    Paloczi, Janos
    Gaspar, Renata
    Kovacs, Laszlo
    Weber, Lutz
    Takacs, Ferenc
    Hajdu, Istvan
    Fabo, Gabriella
    Cseh, Sandor
    Barna, Laszlo
    Csont, Tamas
    Csonka, Csaba
    Dorman, Gyoergy
    Ferdinandy, Peter
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [5] Matrix metalloproteinase inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1998, 3 (10) : 482 - 482
  • [6] Matrix metalloproteinase inhibitors
    Slawomir M. Wojtowicz-Praga
    Robert B. Dickson
    Michael J. Hawkins
    Investigational New Drugs, 1997, 15 : 61 - 75
  • [7] MATRIX METALLOPROTEINASE INHIBITORS
    BROWN, PA
    BORKAKOTI, N
    BOTTOMLEY, KM
    BROADHURST, MJ
    DAREY, A
    HALLAM, TJ
    JOHNSON, WH
    LAWTON, G
    LEWIS, EJ
    MURRAY, EJ
    NIXON, JS
    WILLIAMS, DH
    WINKLER, F
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 207 : 274 - MEDI
  • [8] Matrix metalloproteinase inhibitors
    Lloyd, AW
    DRUG DISCOVERY TODAY, 1998, 3 (08) : 386 - 387
  • [9] Matrix metalloproteinase inhibitors
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (09) : 917 - 920
  • [10] Matrix metalloproteinase inhibitors
    Peter D. Brown
    Angiogenesis, 1997, 1 (2) : 142 - 154